NRAS is found to be mutated in 4-6% of MDS and is shown to predict a phenotype with increased marrow myeloblasts, lower OS, and increased risk of transformation to AML (174), with mutations in KRAS detected in no higher than 1% of cases (175, 176). The gene discussed is NRAS; the disease is myelodysplastic syndrome.